Guardant Health Inc
GH: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$26.00 | Snmq | Wmvbqnhwn |
Guardant Still Going All-in on Pipeline Tests; Reducing FVE by 9% on Tempered Long-Term Growth
Guardant’s second-quarter sales met consensus forecasts aggregated by FactSet, though results fell short of our higher expectations, and we are reducing our fair value estimate to $82. Shares remain moderately undervalued in our view. We are also maintaining our no-moat and positive moat trend ratings.